Fibrogen announces topline results from lelantos-2, a phase 3 clinical study of pamrevlumab in ambulatory duchenne muscular dystrophy

– study did not meet the primary endpoint – – pamrevlumab was generally safe and well tolerated – san francisco, aug. 29, 2023 (globe newswire) -- fibrogen, inc. (nasdaq: fgen) today announced topline data from the phase 3 lelantos-2 trial of pamrevlumab for the treatment of ambulatory patients with duchenne muscular dystrophy (dmd) on background systemic corticosteroids. the study did not meet the primary endpoint of change in the north star ambulatory assessment (nsaa) total score from baseline to week 52 (placebo-corrected mean difference -0.528 points; 95% ci -2.308 to 1.251; p=0.5553).
FGEN Ratings Summary
FGEN Quant Ranking